CheckMate 141: 1-Year Update and Subgroup Analysis of Nivolumab as First-line Therapy in Patients With Recurrent/Metastatic Head and Neck Cancer

Running head: CheckMate 141: First-line Nivolumab in R/M SCCHN

MAURA L. GILLISON,<sup>a</sup> GEORGE BLUMENSCHEIN, JR.,<sup>a</sup> JEROME FAYETTE,<sup>b</sup> JOEL GUIGAY,<sup>c</sup> A. DIMITRIOS COLEVAS,<sup>d</sup> LISA LICITRA,<sup>e</sup> KEVIN J. HARRINGTON,<sup>f</sup> STEFAN KASPER,<sup>g</sup> EVERETT E. VOKES,<sup>h</sup> CAROLINE EVEN,<sup>i</sup> FRANCIS WORDEN,<sup>j</sup> NABIL F. SABA,<sup>k</sup> LARA CARMEN IGLESIAS DOCAMPO,<sup>1</sup> ROBERT HADDAD,<sup>m</sup> TAMARA RORDORF,<sup>n</sup> NAOMI KIYOTA,<sup>o</sup> MAKOTO TAHARA,<sup>p</sup> MANISH MONGA,<sup>q</sup> MARK LYNCH,<sup>q</sup> LI LI,<sup>q</sup> ROBERT L. FERRIS<sup>r</sup>

<sup>a</sup>MD Anderson Cancer Center, Houston, Texas, USA; <sup>b</sup>Centre Leon Berard, Lyon, France; <sup>c</sup>Centre Antoine Lacassagne, FHU OncoAge, Université Côte d'Azur, Nice, France; <sup>d</sup>Stanford University, Stanford, California, USA; <sup>e</sup>Fondazione IRCCS Istituto Nazionale dei Tumori and University of Milan, Milan, Italy; <sup>f</sup>Royal Marsden NHS Foundation Trust/The Institute of Cancer Research, National Institute of Health Research Biomedical Research Centre, London, UK; <sup>g</sup>West German Cancer Center, University Hospital, Essen, Germany; <sup>h</sup>University of Chicago Medicine and Biological Sciences, Chicago, Illinois, USA; <sup>i</sup>Gustave Roussy, Villejuif Cedex, France; <sup>j</sup>University of Michigan, Ann Arbor, Michigan, USA; <sup>k</sup>Winship Cancer Institute of Emory University, Atlanta, Georgia, USA; <sup>1</sup>Hospital Universitario 12 de Octubre, Madrid, Spain; <sup>m</sup>Dana-Farber/Harvard Cancer Center, Boston, Massachusetts, USA; <sup>n</sup>Universitätsspital Zurich, Zurich, Switzerland; <sup>o</sup>Kobe University Hospital Cancer Center, Kobe, Japan;

This is the author manuscript accepted for publication and has undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1634/theoncologist.2017-0674

1

<sup>p</sup>National Cancer Center Hospital East, Kashiwa, Japan; <sup>q</sup>Bristol-Myers Squibb, Princeton, New Jersey, USA; <sup>r</sup>University of Pittsburgh Medical Center Hillman Cancer Center, Pittsburgh, Pennsylvania, USA

Correspondence: Maura L. Gillison, M.D., Ph.D., The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 432, Houston, TX 77030, USA. Telephone: 713-792-6363; Fax: 713-792-1220; e-mail: <u>mgillison@mdanderson.org</u>

Key words: Nivolumab • Head and neck cancer • Programmed cell death 1 inhibitors • Phase III

-----

Author Manuscrip

## **INTRODUCTION**

Patients with squamous cell carcinoma of the head and neck (SCCHN) frequently present with advanced disease and receive combined modality therapy [1]. Unfortunately, 10–15% of patients progress within 6 months of platinum-based therapy and have a poor prognosis, with no established standard of care [2-5]. The CheckMate 141 trial investigated nivolumab vs investigator's choice (IC) of therapy in patients with recurrent or metastatic (R/M) SCCHN. Eligible patients had experienced tumor progression or recurrence within 6 months of platinum-based chemotherapy administered in the locally advanced, recurrent, or metastatic disease setting. Nivolumab significantly extended overall survival (OS) compared with IC (hazard ratio [HR], 0.70; 97.73% confidence interval [CI], 0.51-0.96; p = .01) in the overall study population [6]. Here, we report outcomes among patients who received nivolumab vs. IC as first-line treatment for R/M SCCHN after progressing on platinum therapy for locally advanced disease in the adjuvant or primary (i.e., with radiation) setting, hereafter referred to as first-line treatment for R/M SCCHN. Updated results with longer follow-up in the overall population are also reported.

#### METHODS

In the randomized, open-label, phase III CheckMate 141 (NCT02105636) trial [6], patients were randomized 2:1 to nivolumab (3 mg/kg every 2 weeks) or IC (methotrexate, docetaxel, or cetuximab). The primary endpoint was OS; additional endpoints included progression-free survival (PFS), objective response rate (ORR; per Response Evaluation Criteria In Solid Tumors version 1.1), and safety [6]. In the present post hoc analysis, efficacy and safety were assessed in patients receiving nivolumab vs IC as first-line treatment for R/M SCCHN. Updated results in the overall intent-to-treat population, based on a

database lock of September 2016, are also reported. Cox proportional hazards models were used to estimate HRs and CIs.

CheckMate 141 was registered with the National Cancer Institute and approved by the institutional board at each participating site. All patients provided informed consent prior to enrollment.

#### RESULTS

## First-line Treatment for R/M SCCHN

In all, 78 patients (21.6%) received nivolumab (n = 52) or IC (n = 26) as first-line treatment for R/M SCCHN. The baseline characteristics of these patients (Supplemental Table 1) were similar to those of the overall population [6].

Nivolumab as first-line treatment improved OS vs. IC in patients with R/M SCCHN (median [95% CI], 7.7 [3.1–13.8] vs. 3.3 [2.1–6.4] months; HR [95% CI], 0.56 [0.33–0.95]) (Fig. 1). The 12month OS rate was 39.2% vs. 15.4%, respectively. Median (95% CI) PFS was 2.3 (1.9–3.3) months for nivolumab and 2.3 (1.7–3.2) months for IC; HR, 0.81; 95% CI, 0.48–1.37. The ORR was 19.2% vs. 11.5%, respectively; time to response was 2.0 months in both arms (Supplemental Table 2). Grade 3–4 treatment-related adverse event (TRAE) rates were 27.5% for nivolumab and 32.0% for IC (Supplemental Table 3).

#### **One-Year Follow-up in the Overall Intent-to-Treat Population**

With a minimum follow-up of 11.4 months, 16/240 patients (7%) in the nivolumab arm and 1/121 patients (1%) in the IC arm in the intent-to-treat population were still on treatment (Supplemental Fig. 1). Median (range) duration of therapy was 1.9 (0–24+) months for nivolumab and 1.9 (0–12+) months for

IC. Nivolumab continued to improve OS vs. IC significantly (Fig. 2), with the 18-month OS rate nearly tripled (21.5% vs. 8.3%). OS among subgroups was generally consistent with overall treatment effect (Supplemental Fig. 2). Median (95% CI) PFS was 2.0 (1.9–2.1) months for nivolumab and 2.3 (2.0–3.1) months for IC; HR, 0.87; 95% CI, 0.69–1.11. ORR did not change from the initial analysis [6]; six patients in the nivolumab arm and one patient in the IC arm had a complete response and were alive at last follow-up. As of database lock, three patients were off-study and four patients still on-study had not progressed. Median (range) time to response was 2.1 (1.8–7.4) months for nivolumab vs. 2.0 (1.9–4.6) months for IC. Median (range) duration of response was 9.7 (2.8–20.3+) months vs. 4.0 (1.5+–8.5+) months, respectively.

TRAEs in the overall treated population in the 1-year follow-up were consistent with the initial analysis; longer follow-up identified no new safety signals. Grade 3–4 TRAE rates were 15.3% for nivolumab vs. 36.0% for IC (Supplemental Table 4). Select endocrine TRAEs were more frequent with nivolumab than with IC; none was grade 3–4. Skin-related TRAEs were the most common select TRAEs in both treatment arms.

#### DISCUSSION

Author Manuscrip

Consistent with outcomes in the overall patient population of CheckMate 141, nivolumab as first-line treatment improved OS and ORR compared with IC in patients with R/M SCCHN. PFS was similar with nivolumab vs. IC, as were rates of high-grade TRAEs. Nivolumab is the only agent to significantly improve survival in a randomized phase III trial for platinum-refractory R/M SCCHN. With a minimum follow-up of 11.4 months in the present analysis, efficacy and safety in the overall intent-to-treat population were similar to results at earlier time points [6].

The current standard of care for first-line treatment of platinum-eligible R/M SCCHN is the EXTREME regimen; however, patients with platinum-refractory SCCHN were not included in the EXTREME trial. Patients eligible for CheckMate 141, who were platinum-refractory due to progression within 6 months of treatment in the primary setting, are generally not candidates for platinum-containing therapies such as EXTREME [7]. Their treatment options are limited to methotrexate, taxanes, or cetuximab—the IC options in the CheckMate 141 trial. Nivolumab as first-line treatment for R/M SCCHN resulted in a 12-month OS of 39% in patients with platinum-refractory disease. Furthermore, quality-of-life benefits were observed with nivolumab vs. IC in CheckMate 141 [8].

Although these data represent a small subgroup of patients, the results support the use of nivolumab as first-line therapy for patients with R/M SCCHN who progressed within 6 months of platinum-based therapy in the adjuvant or primary setting. CheckMate 714 (NCT02823574) is an ongoing, randomized, double-blind, phase II study designed to evaluate the clinical benefit of adding anti–CTLA-4 targeted therapy (ipilimumab) to nivolumab for patients with platinum-refractory or platinum-eligible R/M SCCHN [9]. Nivolumab plus ipilimumab is being evaluated in CheckMate 651 as first-line therapy for platinum-eligible R/M disease vs. EXTREME (NCT02741570) [10].

## ACKNOWLEDGMENTS

The authors thank the patients and their families, as well as the clinical study teams, for making this study possible. This study was sponsored by Bristol-Myers Squibb (Princeton, New Jersey) and Ono Pharmaceutical Company Ltd. (Osaka, Japan). Professional medical writing assistance was provided by Virginie Adam, Ph.D., and Beth Burke, Ph.D., C.M.P.P., of Evidence Scientific Solutions, and was funded by Bristol-Myers Squibb.

## REFERENCES

Author Manuscrip

 National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines<sup>®</sup>) Head and Neck Cancers. May 8, 2017.

2. Zenda S, Onozawa Y, Boku N et al. Single-agent docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck (SCCHN). Jpn J Clin Oncol 2007;37:477–481.

3. Machiels JP, Subramanian S, Ruzsa A et al. Zalutumumab plus best supportive care versus best supportive care alone in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck after failure of platinum-based chemotherapy: an open-label, randomised phase 3 trial. Lancet Oncol 2011;12:333–343.

4. de Andrade DA, Machiels JP. Treatment options for patients with recurrent or metastatic squamous cell carcinoma of the head and neck, who progress after platinum-based chemotherapy. Curr Opin Oncol 2012;24:211–217.

5. Nguyen-Tan PF, Zhang Q, Ang KK et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol 2014;32:3858–3866.

6. Ferris RL, Blumenschein G, Jr., Fayette J et al. Nivolumab for recurrent squamous-cell carcinoma of the head and neck. N Engl J Med 2016;375:1856–1867.

7. Vermorken JB, Mesia R, Rivera F et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008;359:1116–1127.

8. Harrington KJ, Ferris RL, Blumenschein G, Jr. et al. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial. Lancet Oncol 2017;18:1104–1115.

9. Haddad R, Gillison M, Ferris RL et al. Double-blind, two-arm, phase 2 study of nivolumab (nivo) in combination with ipilimumab (ipi) versus nivo and ipi-placebo (PBO) as first-line (1L) therapy in patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)—CheckMate 714 [abstract]. Ann Oncol 2016;27(suppl 6):1017TiP.

10. Argiris A, Gillison M, Ferris RL et al. A randomized, open-label, phase 3 study of nivolumab in combination with ipilimumab vs extreme regimen (cetuximab + cisplatin/carboplatin + fluorouracil) as first-line therapy in patients with recurrent or metastatic squamous cell carcinoma of the head and neck-CheckMate 651 [abstract]. Ann Oncol 2016;27(suppl 6):1016TiP.

-

# FIGURE LEGENDS

**Figure 1.** OS (A) and treatment effect on OS (B) among patients randomized to nivolumab or IC as firstline treatment for R/M SCCHN after progressing on or after platinum therapy (within 6 months) in the adjuvant or primary (i.e., with radiation) setting for locally advanced disease.

Abbreviations: CI, confidence interval; HPV, human papillomavirus; HR, hazard ratio; IC, investigator's choice; NE, not estimable; Nivo, nivolumab; OS, overall survival; R/M, recurrent or metastatic; SCCHN, squamous cell carcinoma of the head and neck.

Figure 2. OS in the overall intent-to-treat population.

Abbreviations: CI, confidence interval; HR, hazard ratio; IC, investigator's choice; Nivo, nivolumab; OS, overall survival.

Supplemental Figure 1. CONSORT diagram.

Abbreviations: R/M, recurrent or metastatic; SCCHN, squamous cell carcinoma of the head and neck.

**Supplemental Figure 2.** Treatment effect on overall survival by subgroup for the overall intent-to-treat population.


<sup>a</sup>Stratification factor.

Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HPV, human papillomavirus; HR, hazard ratio; IC, investigator's choice; Nivo, nivolumab.

Author Manuscrip

# FIGURES

Figure 1.




В	

D	n	Nivolumab Median OS (95% Cl), mo	n	IC Median OS (95% Cl), mo	Unstratified HR (95% CI)	Favors Nivo Favors IC
Overall	52	7.7 (3.1–13.8)	26	3.3 (2.1–6.4)	0.56 (0.33–0.95)	- <b>-</b> -
HPV status						
Positive	10	NE (2.3–NE)	6	3.0 (1.9–13.6)	0.30 (0.09–1.02)	<b>_</b>
Negative	15	7.7 (1.9–NE)	8	8.4 (1.7–NE)	0.84 (0.30–2.37)	<b>●</b>
Not reported	27	5.3 (2.4–9.1)	12	2.2 (1.0–6.3)	0.49 (0.23–1.01)	

0.062 0.125 0.25 0.5 1 2 4 Unstratified HR (95% Cl) Nivo vs. IC

8





# SUPPLEMENTARY DATA

**Supplemental Table 1.** Baseline characteristics among patients randomized to nivolumab or investigator's choice as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck after progressing on or after platinum therapy (within 6 months) in the adjuvant or primary (i.e., with radiation) setting for locally advanced disease.

	Nivolumab	Investigator's choice
Characteristics	( <i>n</i> = 52)	(n = 26)
Age, median (range), years	57.5 (30–79)	59.5 (28–78)
Age $\geq 65$ years, $n$ (%)	13 (25.0)	9 (34.6)
Male, <i>n</i> (%)	41 (78.8)	21 (80.8)
Race, <i>n</i> (%)		
White	37 (71.2)	24 (92.3)
Black	4 (7.7)	1 (3.8)
Asian	9 (17.3)	1 (3.8)
Other	2 (3.8)	0
Region, <i>n</i> (%)		
North America	21 (40.4)	5 (19.2)
Europe	22 (42.3)	18 (69.2)
Rest of the world	9 (17.3)	3 (11.5)
Smoking or tobacco use, n (%)		
Current/former	40 (76.9)	17 (65.4)
Never	10 (19.2)	8 (30.8)
Unknown	2 (3.8)	1 (3.8)

## HIGHLY CONFIDENTIAL

	Nivolumab	Investigator's choice
Characteristics	(n = 52)	(n = 26)
0	11 (21.2)	5 (19.2)
1	41 (78.8)	20 (76.9)
2	0	1 (3.8)
HPV status, n (%)		
Positive	10 (19.2)	6 (23.1)
Negative	15 (28.8)	8 (30.8)
Not tested <sup>a</sup>	27 (51.9)	12 (46.2)
PD-L1 expression, <i>n</i> (%)		
≥1%	24 (46.2)	14 (53.8)
<1%	13 (25.0)	7 (26.9)
Not quantifiable	15 (28.8)	5 (19.2)

<sup>a</sup>HPV status testing only required for patients with oropharyngeal cancer.

Abbreviations: ECOG, Eastern Cooperative Oncology Group; HPV, human papillomavirus; PD-L1, programmed death ligand 1.

**Supplemental Table 2.** Response among patients receiving nivolumab or investigator's choice as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck after progressing on or after platinum therapy (within 6 months) in the adjuvant or primary (i.e., with radiation) setting for locally advanced disease.

	Nivolumab	Investigator's choice
	(n = 52)	(n = 26)
Best overall response, n (%)		
Complete response	2 (3.8)	0
Partial response	8 (15.4)	3 (11.5)
Stable disease	11 (21.2)	8 (30.8)
Progressive disease	18 (34.6)	8 (30.8)
Unable to determine	13 (25.0)	7 (26.9)
<b>DRR</b> , <i>n</i> (%)	10 (19.2)	3 (11.5)
[95% CI]	[9.6–32.5]	[1.2–10.4]
Odds ratio (95% CI)	1.83 (0.46–7.31)	
Fime to response, median (range), months	2.0 (1.8-6.3)	2.0 (1.9-4.6)

Abbreviations: CI, confidence interval; ORR, objective response rate.

**Supplemental Table 3.** Most common TRAEs ( $\geq$ 10% in any arm) and select TRAEs among patients receiving nivolumab or investigator's choice as first-line treatment for recurrent or metastatic squamous cell carcinoma of the head and neck after progressing on or after platinum therapy (within 6 months) in the adjuvant or primary (i.e., with radiation) setting for locally advanced disease.

	Nivolumab		Investigator's choice $(n = 25)$		
	(n = 51)				
Patients, n (%)	Any grade	Grade 3–4	Any grade	Grade 3–4	
Any event (≥10% in any arm)	35 (68.6)	14 (27.5)	18 (72.0) <sup>a</sup>	8 (32.0)	
Fatigue	9 (17.6)	3 (5.9)	3 (12.0)	0	
Nausea	7 (13.7)	0	5 (20.0)	0	
Pruritus	6 (11.8)	0	0	0	
Asthenia	4 (7.8)	0	5 (20.0)	1 (4.0)	
Vomiting	3 (5.9)	0	3 (12.0)	0	
Dry skin	2 (3.9)	0	3 (12.0)	0	
Mucosal inflammation	1 (2.0)	0	5 (20.0)	0	
Alopecia	0	0	4 (16.0)	0	
Select TRAEs					
Skin	10 (19.6)	0	4 (16.0)	1 (4.0)	
Endocrine	4 (7.8)	0	0	0	
Gastrointestinal	4 (7.8)	1 (2.0)	2 (8.0)	0	
Hepatic	3 (5.9)	0	1 (4.0)	0	
Pulmonary	1 (2.0)	0	1 (4.0)	0	
Renal	1 (2.0)	0	0	0	
Hypersensitivity/infusion reactions	2 (3.9)	0	1 (4.0)	1 (4.0)	

<sup>a</sup>Includes 1 grade 5 event of pneumonia.

Abbreviation: TRAE, treatment-related adverse event.

Supplemental Table 4. Most common TRAEs (≥10% in any arm) and select TRAEs in the overall treated


population.

Nivolumab		Investigator's choice $(n = 111)$		
(n = 236)				
Any grade	Grade 3–4	Any grade	Grade 3–4	
146 (61.9)	36 (15.3)	88 (79.3) <sup>a</sup>	40 (36.0)	
37 (15.7)	5 (2.1)	20 (18.0)	3 (2.7)	
22 (9.3)	0	23 (20.7)	1 (0.9)	
20 (8.5)	1 (0.4)	16 (14.4)	2 (1.8)	
12 (5.1)	3 (1.3)	19 (17.1)	6 (5.4)	
10 (4.2)	1 (0.4)	17 (15.3)	2 (1.8)	
6 (2.5)	1 (0.4)	12 (10.8)	3 (2.7)	
4 (1.7)	0	15 (13.5)	2 (1.8)	
0	0	14 (12.6)	0	
40 (16.9)	0	14 (12.6)	2 (1.8)	
22 (9.3)	1 (0.4)	1 (0.9)	0	
20 (8.5)	1 (0.4)	17 (15.3)	2 (1.8)	
7 (3.0)	2 (0.8)	5 (4.5)	1 (0.9)	
7 (3.0)	2 (0.8)	1 (0.9)	0	
3 (1.3)	0	2 (1.8)	1 (0.9)	
3 (1.3)	0	2 (1.8)	1 (0.9)	
	(n = 236) Any grade $146 (61.9)$ 37 (15.7) 22 (9.3) 20 (8.5) 12 (5.1) 10 (4.2) 6 (2.5) 4 (1.7) 0 40 (16.9) 22 (9.3) 20 (8.5) 7 (3.0) 7 (3.0) 3 (1.3)	( $n = 236$ )Any gradeGrade 3-4146 (61.9)36 (15.3)37 (15.7)5 (2.1)22 (9.3)020 (8.5)1 (0.4)12 (5.1)3 (1.3)10 (4.2)1 (0.4)6 (2.5)1 (0.4)4 (1.7)00040 (16.9)022 (9.3)1 (0.4)20 (8.5)1 (0.4)7 (3.0)2 (0.8)7 (3.0)2 (0.8)3 (1.3)0	(n = 236) $(n = 111)$ Any gradeGrade 3-4Any grade146 (61.9)36 (15.3)88 (79.3)a37 (15.7)5 (2.1)20 (18.0)22 (9.3)023 (20.7)20 (8.5)1 (0.4)16 (14.4)12 (5.1)3 (1.3)19 (17.1)10 (4.2)1 (0.4)17 (15.3)6 (2.5)1 (0.4)12 (10.8)4 (1.7)015 (13.5)0014 (12.6)22 (9.3)1 (0.4)1 (0.9)20 (8.5)1 (0.4)1 (0.9)20 (8.5)1 (0.4)17 (15.3)7 (3.0)2 (0.8)5 (4.5)7 (3.0)2 (0.8)1 (0.9)3 (1.3)02 (1.8)	

<sup>a</sup>Includes 1 grade 5 event of pneumonia.

Abbreviation: TRAE, treatment-related adverse event.

# Supplemental Figure 1. CONSORT diagram.



Supplemental Figure 2. Treatment effect on overall survival by subgroup for the overall intent-to-treat population.

	Nivo n	IC n	Unstratified HR (95% Cl)	Favors Nivo Favors IC
Overall	240	121	0.70 (0.55–0.90)	- <b>-</b>
Age category				
<65 years	172	76	0.66 (0.49–0.89)	<b>——</b> –
≥65 years	68	45	0.79 (0.52–1.19)	<b>+</b>
ECOG PS				
0	49	23	0.62 (0.33–1.16)	<b>—</b> •
≥1	190	97	0.72 (0.55–0.94)	<b></b>
Prior cetuximab use <sup>a</sup>				
Yes	147	74	0.84 (0.62–1.15)	
No	93	47	0.52 (0.35–0.77)	<b>——</b>
Intended IC				
Cetuximab	33	15	0.39 (0.20–0.76)	<b>_</b>
Methotrexate	119	52	0.62 (0.44–0.89)	<b></b>
Docetaxel	88	54	0.91 (0.62–1.33)	<b></b>
HPV status				
Positive	63	29	0.63 (0.38–1.04)	<b></b>
Negative	55	37	0.64 (0.40–1.03)	<b>_</b> _
Unknown	122	55	0.78 (0.55–1.10)	
Site of primary tumor				
Larynx	34	14	0.89 (0.44–1.83)	•
Oral cavity	108	67	0.73 (0.53–1.02)	<b></b>
Pharynx	92	37	0.68 (0.44–1.04)	<b>—•</b> –
Prior lines of systemic therapy				
1	106	58	0.70 (0.49–0.99)	
2	80	44	0.69 (0.46–1.04)	<b></b>
≥3	54	19	0.71 (0.39–1.28)	
			(	0.125 0.25 0.5 1 2 4 Unstratified HR (95% Cl)

<sup>a</sup>Stratification factor.

Author Manuscript

Abbreviations: CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group performance status; HPV, human papillomavirus; HR, hazard ratio; IC, investigator's choice; Nivo, nivolumab.